Research Activity
MBX Secures $63.5M in Funding Ahead of Clinical Readouts
MBX, clinical readouts, funding, engineered peptide therapeutics, hypoparathyroidism, Phase II trial
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case
Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Vertex Pharmaceuticals Abandons Two Phase I AATD Drug Candidates Due to Disappointing Data
Vertex Pharmaceuticals, AATD, alpha-1 antitrypsin deficiency, drug candidates, Phase I trials, disappointing data
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies
Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case
Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma
GSK Partners with Flagship Pioneering in $7 Billion Biobucks Deal for Respiratory and Immunology Research
GSK, Flagship Pioneering, biobucks, respiratory research, immunology research, pharmaceutical partnership
Healx Initiates Phase II Trial for AI-Discovered Rare Disease Candidate with $47M Funding
Healx, AI-discovered, rare disease, neurofibromatosis Type 1, Phase II trial, $47M funding
Biopharma Companies uniQure and Arbutus Announce Workforce Reductions to Focus on Priority Programs
uniQure, Arbutus Biopharma, layoffs, workforce reduction, biopharma, priority programs, gene therapy, clinical trials